US20220002703A1 - Adamts13-containing compositions having thrombolytic activity - Google Patents
Adamts13-containing compositions having thrombolytic activity Download PDFInfo
- Publication number
- US20220002703A1 US20220002703A1 US17/478,520 US202117478520A US2022002703A1 US 20220002703 A1 US20220002703 A1 US 20220002703A1 US 202117478520 A US202117478520 A US 202117478520A US 2022002703 A1 US2022002703 A1 US 2022002703A1
- Authority
- US
- United States
- Prior art keywords
- adamts13
- mice
- thrombus
- platelets
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 9
- 101100325621 Mus musculus Adamts13 gene Proteins 0.000 title description 18
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 95
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 57
- 102000043853 ADAMTS13 Human genes 0.000 claims abstract description 28
- 108091005670 ADAMTS13 Proteins 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 101000798281 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 13 Proteins 0.000 claims description 18
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 18
- 102000057210 human ADAMTS13 Human genes 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 14
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims description 7
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims description 7
- 208000022774 Congenital thrombotic thrombocytopenic purpura Diseases 0.000 claims description 6
- 206010047249 Venous thrombosis Diseases 0.000 claims description 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 description 88
- 108010047303 von Willebrand Factor Proteins 0.000 description 56
- 102100036537 von Willebrand factor Human genes 0.000 description 56
- 229960001134 von willebrand factor Drugs 0.000 description 53
- 210000002565 arteriole Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 29
- 230000006378 damage Effects 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 208000014674 injury Diseases 0.000 description 25
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 24
- 210000000264 venule Anatomy 0.000 description 24
- 210000003038 endothelium Anatomy 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 22
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 19
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 19
- 238000001802 infusion Methods 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 14
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 11
- 210000004269 weibel-palade body Anatomy 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000000713 mesentery Anatomy 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000002785 anti-thrombosis Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091022879 ADAMTS Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 102000029750 ADAMTS Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 102000008607 Integrin beta3 Human genes 0.000 description 4
- 108010020950 Integrin beta3 Proteins 0.000 description 4
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000012771 intravital microscopy Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- -1 GAP Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 210000003815 abdominal wall Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150085726 ADAMTS13 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101800000620 Disintegrin-like Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 208000013607 Glanzmann thrombasthenia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000000392 Thrombasthenia Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001407 anti-thrombic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229940034998 human von willebrand factor Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012576 optical tweezer Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to pharmaceutical compositions having thrombolytic activity comprising a pharmaceutically effective amount of ADAMTS13, to methods of treating or preventing disorders associated with the formation and/or the presence of one or more thrombus as well as to methods for disintegrating one or more thrombus in a patient in need thereof.
- the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
- Thrombotic thrombocytopenic purpura is a disorder characterized by thrombotic microangiopathy, thrombocytopenia and microvascular thrombosis that can cause various degrees of tissue ischemia and infarction.
- TTP patients are diagnosed by symptoms such as thrombocytopenia, schistocytes (fragments of erythrocytes) and elevated levels of lactate dehydrogenase (Moake J L. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600; Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol.
- the protease belongs to the ADAMTS family and is designated as ADAMTS13 (A Disintegrin-like And Metalloprotease with Thrombospondin type I repeats), a 190 kDa glycosylated protein produced predominantly by the liver (Levy G G, Nichols W C, Lian E C, Foroud T, McClintick J N, McGee B M, Yang A Y, Siemieniak D R, Stark K R, Gruppo R, Sarode R, Shurin S B, Chandrasekaran V, Stabler S P, Sabio H, Bouhassira E E, Upshaw J D, Jr., Ginsburg D, Tsai H M.
- ADAMTS13 A Disintegrin-like And Metalloprotease with Thrombospondin type I repeats
- Idiopathic TTP is a more common disorder that occurs in adults and older children and can recur at regular intervals in 11-36% of patients (Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594; Furlan M, Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol. 1998;11:509-514).
- Non neutralizing autoantibodies could also inhibit ADAMTS activity by inducing clearance from circulation (Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003 ; 102 : 3241 -3243). Plasma ADAMTS13 activity in healthy adults ranges from 50% to 178% (Moake J L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med. 2002;126:1430-1433).
- ADAMTS13 activity is absent or less than 5% of the normal. Without treatment the mortality rate exceeds 90%, but plasma therapy has reduced mortality to about 20% (Moake J L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med. 2002;126:1430-1433).
- vWF synthesized in megakaryocytes and endothelial cells is stored in platelet ⁇ -granules and Weibel-Palade bodies, respectively, as ultra large vWF (UL-vWF) 5.
- UL-vWF ultra large vWF
- Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun. 1989;158:980-985; Tsai H M, Nagel R L, Hatcher V B, Sussman, II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989;73:2074-2076). Once secreted from endothelial cells, these UL-vWF multimers are cleaved by ADAMTS13 in circulation into a series of smaller multimers at specific cleavage sites within the vWF molecule (Tsai H M, Nagel R L, Hatcher V B, Sussman, II.
- Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun. 1989;158:980-985; Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88:774-782; Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lammle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA. 1993;90:7503-7507).
- vWF exists in “ball-of-yarn” and filamentous form as seen by electron microscopy (Slayter H, Loscalzo J, Bockenstedt P, Handin R I. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering.
- UL-vWF multimers present in Weibel-Palade bodies, when released by activated endothelial cells bind platelets more tightly (through GPIb ⁇ ) than plasma vWF (27. Arya M, Anvari B, Romo G M, Cruz M A, Dong J F, McIntire L V, Moake J L, Lopez J A. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99:3971-397).
- ADAMTS13 ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639).
- Thrombi of TTP patients consist of little fibrin and mainly of vWF and platelets, suggesting vWF-mediated platelet aggregation as a cause of thrombosis (30.
- Patients with relapsing TTP have ultra-large multimers in the plasma.
- the UL-vWF multimers accumulate over time because the persistence of the inhibitor (Anti-ADAMTS13 Ab) decreases ADAMTS13 activity.
- the UL-vWF multimers are hyperactive and unfold as a result of shear stress causing platelet aggregation, resulting in intravascular thrombosis (Tsai H M. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med. 2002;80:639-647; Tsai H M. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. J Thromb Haemost. 2003;1:2038-2040; discussion 2040-2035).
- An object of the present invention is to provide a pharmaceutical composition having thrombolytic activity.
- the pharmaceutical composition comprises a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof, and optionally one or more pharmaceutically acceptable carrier and/or diluent. Said composition may also comprise one or more additional active ingredient. Further, the present invention relates to a method of treating or preventing a disorder associated with the formation and/or presence of one or more thrombus and to a method of disintegrating one or more thrombus in a patient in need thereof.
- a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof can be used for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
- Said pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof may range, for example, from 0.1 to 20 mg/kg body weight.
- FIG. 1 Thrombus formation in microvenules.
- Mesenteric venules of approx. 25-30 ⁇ m in diameter were visualized after an incision was made through the abdominal wall to expose the mesentery of live mice.
- the arrows indicate the microthrombi.
- stimulation of Weibel-Palade body secretion can lead to spontaneous thrombus formation in Adamts13 ⁇ / ⁇ mice in the absence of vascular injury.
- Inset time points in lower right corner refer to the time after superfusion of A23187. Bar shown in the middle panel is (approx.) 50 ⁇ m.
- Inset time points in lower right corner refer to the time after superfusion of A23187. Bar shown in the middle panel is (approx.) 25 ⁇ m.
- FIG. 4 Recombinant ADAMTS13 inhibits platelet strings in Adamts13 ⁇ / ⁇ mice.
- Rhodamin 6G was used to label endogenous platelets and leukocytes. 1 mM histamine (200 ⁇ l) was administered i.p. 15 mins before surgery and 3 mesenteric venules of approx. 200-300 m in diameter were visualized per mouse.
- A: No platelet strings are seen in Adamts13 WT mice (n 5).
- C The platelet strings could form platelet aggregates in Adamts13 ⁇ / ⁇ mice as indicated by arrowhead.
- FIG. 5 Quantitative analysis of platelet adhesion and thrombi formation in arterioles of WT and Adamts 13 ⁇ / ⁇ mice.
- A The number of fluorescent platelets deposited per minute was determined in the interval 2-3 min after injury (total number of adherent platelets counted in 1 min interval). For statistics and mean, platelets greater than 100 was considered as 100. Absence of ADAMTS13 in the plasma clearly influences the early platelet interaction with the subendothelium. Compared with WT, in Adamts 13 ⁇ / ⁇ more platelets were deposited on the vessel wall (P ⁇ 0.05).
- D Fluorescently-labeled platelets representing approx. 2.5% of total platelets were observed in mesenteric arterioles of live mice after ferric chloride injury. Blood flow was from left to right. Inset time points in lower right corner refer to the time after injury. Single adherent platelets are seen in the arteriole at 4 min after injury in the WT, whereas a thrombus (approx. 30 ⁇ m) can already be seen in the Adamts13 ⁇ / 31 mouse arteriole at the same time point. The vessel was occluded at 10 min by a thrombus at the site of injury in Adamts13 ⁇ / 31 mice, while the WT mouse arteriole remained opened at that time. Photographs are representative of 10 mice of each genotype.
- FIG. 6 Inhibition of integrin ⁇ IIb ⁇ 3 blocks thrombus formation of ADAMTS13 ⁇ / 31 platelets on collagen under arterial shear rate conditions.
- Adamts13+/+ or Adamts13 ⁇ / ⁇ whole blood was perfused for 2 min over a collagen surface at a shear rate of 1500s- 1 .
- FIG. 7 Infusion of recombinant human ADAMTS13 inhibits thrombus growth.
- Recombinant human ADAMTS13 was infused (i.v.) in the Adamts13 ⁇ / ⁇ mice 15 min before the ferric chloride injury.
- the occlusion time blood flow completely stopped for 10 sec was determined.
- C Representative fluorescent images of injured arteriole of an Adamts13 ⁇ / ⁇ mouse treated with r-hu ADAMTS13 are shown. Arrowheads indicate a disintegrating thrombus.
- FIG. 8 Infusion of recombinant mouse ADAMTS13 inhibits thrombus growth in WT mice.
- Recombinant mouse ADAMTS13 (2.6 mg/kg mouse) was infused (i.v.) into the WT mice 5 min before the ferric chloride injury.
- FIG. 9 Table 1: Hemodynamic parameters prior to and after application of A23187 on venules ( FIG. 1 ); Table 2: Hemodynamic parameters prior to and after application of ferric chloride on arterioles ( FIG. 5 ).
- One aspect of the present invention relates to a pharmaceutical composition having thrombolytic activity, comprising a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof.
- thrombolytic activity means the disintegration of one or more thrombus. Suitable methods for the determination of thrombolytic activity are well known in the art. For example, suitable methods are the determination of the lysis of a whole blood clot using tPA or streptokinase, or the determination of the thrombus lysis in vivo.
- disintegration includes the partial or complete disintegration, dissolving, dissolution, destruction and/or lysis of a thrombus.
- thrombus as used herein comprises a blood clot, especially a platelet-comprising blood clot, a microthrombus, and/or an embolus. Said thrombus may be attached to an arterial or venous blood vessel or not, and may partially or completely block the blood flow in an arterial or venous blood vessel.
- biologically active derivative means any polypeptides with substantially the same biological function as ADAMTS13.
- the polypeptide sequences of the biologically active derivatives may comprise deletions, additions and/or substitution of one or more amino acids whose absence, presence and/or substitution, respectively, do not have any substantial negative impact on the biological activity of polypeptide.
- the biological activity of said polypeptides may be measured, for example, by the reduction or delay of platelet adhesion to the endothelium, the reduction or delay of platelet aggregation, the reduction or delay of the formation of platelet strings, the reduction or delay of thrombus formation, the reduction or delay of thrombus growth, the reduction or delay of vessel occlusion, the proteolytical cleavage of vWF, and/or the disintegration of thrombi.
- ADAMTS13 and “biologically active derivative”, respectively, also include polypeptides obtained via recombinant DNA technology.
- the recombinant ADAMTS13 (“rADAMTS1 3 ”), e.g. recombinant human ADAMTS13 (“r-hu-ADAMTS13”), may be produced by any method known in the art.
- rADAMTS1 3 e.g. recombinant human ADAMTS13 (“r-hu-ADAMTS13”
- r-hu-ADAMTS13 recombinant human ADAMTS13
- r-hu-ADAMTS13 recombinant human ADAMTS13
- This may include any method known in the art for (i) the production of recombinant DNA by genetic engineering, e.g.
- RNA and/or amplification of DNA via reverse transcription of RNA and/or amplification of DNA, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by transfection, i.e. via electroporation or microinjection, (iii) cultivating said transformed cells, e.g. in a continous or batchwise manner, (iv) expressing ADAMTS13, e.g. constitutively or upon induction, and (v) isolating said ADAMTS13, e.g. from the culture medium or by harvesting the transformed cells, in order to (vi) obtain substantially purified recombinant ADAMTS13, e.g. via anion exchange chromatography or affinity chromatography.
- biologically active derivative includes also chimeric molecules such as e.g. ADAMTS13 (or a biologically active derivative thereof) in combination with Ig, in order to improve the biological/pharmacological properties such as e.g. half life of ADAMTS13 in the circulation system of a mammal, particularly human.
- the Ig could have also the site of binding to an optionally mutated Fc receptor.
- the rADAMTS13 can be produced by expression in a suitable prokaryotic or eukaryotic host system characterized by producing a pharmacologically effective ADAMTS13 molecule.
- eukaryotic cells are mammalian cells, such as CHO, COS, HEK 293, BHK, SK-Hep, and HepG2.
- reagents or conditions used for producing or isolating ADAMTS13 according to the present invention and any system known in the art or commercially available can be employed.
- rADAMTS13 is obtained by methods as described in the state of the art.
- vectors can be used for the preparation of the rADAMTS13 and can be selected from eukaryotic and prokaryotic expression vectors.
- vectors for prokaryotic expression include plasmids such as pRSET, pET, pBAD, etc., wherein the promoters used in prokaryotic expression vectors include lac, trc, trp, recA, araBAD, etc.
- vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as pAO, pPIC, pYES, pMET, using promoters such as AOX1, GAP, GAL1, AUG1, etc; (ii) for expression in insect cells, vectors such as pMT, pAc5, pIB, pMIB, pBAC, etc., using promoters such as PH, p10, MT, Ac5, OpIE2, gp64, polh, etc., and (iii) for expression in mammalian cells, vectors such as pSVL, pCMV, pRc/RSV, pcDNA3, pBPV, etc., and vectors derived form viral systems such as vaccinia virus, adeno-associated viruses, herpes viruses, retroviruses, etc., using promoters such as CMV, SV40, EF-1, UbC, RSV, ADV, BPV,
- the pharmaceutical composition of the present invention also comprises one or more pharmaceutically acceptable carrier and/or diluent.
- the pharmaceutical composition of the present invention may also comprise one or more additional active ingredients such as e.g. anti-thrombotic agents, agents that stimulate ADAMTS13 production/secretion by the treated patient/individual, agents that inhibit the degradation of ADAMTS13 and thus prolonging its half life, agents that enhance ADAMTS13 activity (for example by binding to ADAMTS13, thereby inducing an activating conformational change), or agents that inhibit ADAMTS13 clearance from circulation, thereby increasing its plasma concentration.
- additional active ingredients such as e.g. anti-thrombotic agents, agents that stimulate ADAMTS13 production/secretion by the treated patient/individual, agents that inhibit the degradation of ADAMTS13 and thus prolonging its half life, agents that enhance ADAMTS13 activity (for example by binding to ADAMTS13, thereby inducing an activating conformational change), or agents that inhibit ADAMTS13 clearance from circulation, thereby increasing its plasma concentration.
- anti-thrombotic agents include anti-platelets, t-
- the present invention further relates to a method of treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus, comprising the step of administering a composition according to the invention to a patient.
- Said disorder may be due to hereditary defects, inflammatory diseases, stroke or septic conditions.
- disorders associated with the formation and/or the presence of one or more thrombus are hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, disseminated intravascular coagulation (DIC), and venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
- Another aspect of the present invention relates to a method of disintegrating one or more thrombus in a patient, comprising the step of administering a composition according to the present invention to said patient.
- the route of administration of the composition of the present invention does not exhibit a specific limitation and can be, for example, subcutaneous or intravenous.
- the term “patient” as used in the present invention includes mammals, particularly human.
- the present invention relates to the use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus.
- Another aspect of the present invention is the use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of a pharmaceutical composition for disintegrating one or more thrombus in a patient in need thereof.
- the pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof may range, for example, from 0.1 to 20 mg/kg body weight.
- Example 1 Endothelial activation results in thrombi formation in microvenules of Adamts 13 ⁇ / ⁇ mice
- A23187 a secretagouge of Weibel-Palade bodies activated with calcium ionophore A23187 (a secretagouge of Weibel-Palade bodies) at low shear rate (approx. 100 s ⁇ 1 ) in Adamts13 ⁇ / 31 mice has been observed compared with WT. It was investigated whether activation of microvenule endothelium by A23187 could result in platelet aggregation resulting in thrombus formation. A23187 does not denude the endothelium (Andre P, Denis C V, Ware J, Saffaripour S, Hynes R O, Ruggeri Z M, Wagner D D.
- Example 2 An antibody to ADAMTS13 induces formation of platelets strings in venules of WT mice.
- Example 3 ADAMTS13 inhibitor results in thrombi formation in microvenules in WT mice
- Example 4 Histamine induces platelets strings in the venules of Adamts13 ⁇ / ⁇ mice, whereas, recombinant ADAMTS13 inhibits the formation
- Example 5 Platelet binding to sub endothelium is increased in Adamts13 ⁇ / ⁇ mice
- Ferric chloride (FeCl 3 ) injury leads to deendothelization and exposes sub endothelium (Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392). Platelet subendothelial interactions after injury at arterial shear are initiated by GPIb-vWF interaction and then propagated by other receptors (Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D.
- Example 6 Accelerated thrombus formation in injured arterioles of Adamts13 ⁇ / ⁇ mice
- vWF present in the plasma is either constitutively synthesized by endothelial cells or is secreted in the form of unusually large multimers from the platelet a-granules and endothelial Weibel-Palade bodies upon activation.
- UL-vWF is the most adhesive and reactive form of vWF and may lead to platelet aggregation resulting in a thrombus if not processed by ADAMTS13.
- ferric chloride thrombosis model in the Adamts13 ⁇ / 31 mice thrombi grew faster as thrombi greater than 30 ⁇ m were seen at 6.64 ⁇ 0.93 min compared to 10.78 ⁇ 0.80 min in the WT mice and the results were statistically significant (P ⁇ 0.005, FIG.
- Example 7 ADAMTS13-deficiency enhances thrombus growth in a ⁇ IIb ⁇ 3 integrin-dependent manner
- Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival J Clin Invest 1999;103:229-238) would induce thrombus formation after ferric chloride injury.
- Example 8 Infusion of recombinant human ADAMTS13 in Adamts13 ⁇ / ⁇ or WT (C57BL/6J) mice inhibits thrombus growth by destabilizing the platelet aggregate or thrombus
- r-hu ADAMTS13 corrects the vWF cleavage defect in hereditary TTP plasma (Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt J D, Laemmle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura. Br J Haematol 2003;120:821-824). Since accelerated growth of thrombi in Adamts13 ⁇ / ⁇ mice has been observed, it is hypothesized that ADAMTS13 negatively modulates thrombus growth and therefore infusion of r-hu ADAMTS-13 in Adamts13 ⁇ / ⁇ mice could delay thrombus formation.
- the concentration of the circulating human protein was approximately 8.8 U/ml 17 min after infusion and 1.1 U/ml 53 min after infusion of r-hu ADAMTS13 into Adamts13 ⁇ / ⁇ mice. These times correspond approximately to the onset of ferric chloride injury and the termination of the experiment.
- the effect of the infused r-hu ADAMTS13 was more than that of endogenous ADAMTS13 in WT mice as in this injury model all WT vessels occluded at less than 24 min ( FIG. 5C ).
- Example 9 Infusion of recombinant mouse ADAMTS13 inhibits thrombus growth in WT mice
- Western analysis of the plasma samples taken at the end of the experiment showed that the shorter occlusion time in some of the mice infused with r-ADAMTS13 (similar to WT) was due to increased clearance of the recombinant protein.
- mouse ADAMTS13 appears to have the same anti-thrombotic potential as the human ADAMTS13 in WT mice with normal levels of endogenous ADAMTS protein.
- mice used in the examples were siblings obtained from crosses of Adamts13+/ ⁇ mice on C57BL/6J/129Sv background (Motto D G, Chauhan A K, Zhu G, Homeister J, Lamb C B, Desch K C, Zhang W, Tsai H M, Wagner D D, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115:2752-2761).
- the mice of pure C57BI/6J background were purchased from the Jackson Laboratory, Bar Harbor, Me. and beta3 integrin ⁇ / 31 mice on Balb/C bacjground were a gift from Richard Hynes (MIT).
- mice used for intravital microscopy were young mice (approx. 4 weeks old), both male and female, weighing 14 to 18 grams. Infused platelets were isolated from 4 to 6 months old mice of the same genotype. Animals were bred and housed at CBR Institute for Biomedical Research and all experimental procedures were approved by its Animal Care and Use Committee.
- Calcium ionophore A23187 and ferric chloride were from Sigma Chemicals, St. Louis, Mo.
- Blood was harvested from the retro-orbital venous plexus by puncture and collected in 1.5 ml polypropylene tubes comprising 300 ⁇ l of heparin (30 U/ml).
- Platelet rich plasma (PRP) was obtained by centrifugation at 1200 rpm for 5 min.
- the plasma and buffy coat comprising some RBCs were gently transferred to fresh polypropylene tubes and recentrifuged at 1200 rpm for 5 min.
- the PRP was transferred to fresh tubes comprising 2 ⁇ l of PGI 2 (2 ⁇ g/ml) and incubated at 37° C. for 5 min.
- pellets were resuspended in 1 ml modified Tyrode's-HEPES buffer (137 mM NaCl, 0.3 mM Na 2 HPO 4 , 2 mM KCl, 12 mM NaHCO 3 , 5 mM HEPES, 5 mM glucose, 0.35% BSA) comprising 2 ⁇ l of PGI 2 and incubated at 37° C. for 5 min.
- the suspended pellet was centrifuged at 2800 rpm for 5 min.
- the washing step was repeated twice and platelets were fluorescently labeled with calcein AM 0.25 mg/mL (Molecular Probes, Eugene, Oreg.) for 10 min at room temperature.
- Polyclonal rabbit anti-human ADAMTS13 IgG was produced by Baxter Bioscience, Vienna Austria. The antibody was obtained by immunization of New Zealand white rabbits with purified r-hu ADAMTS13, C-terminally tagged with six His residues. Two rabbits were immunized by injection of 20 ⁇ g of r-hu ADAMTS13 (6-His) in 200 ⁇ l of complete Freund's adjuvant. The animals were boostered after two, four and six weeks by injecting 20 ⁇ g of r-hu ADAMTS13 (6-His) in 200 ⁇ l of incomplete Freund's adjuvant. After eight weeks the rabbits were sacrificed and bled. IgG antibodies were purified by Protein G affinity chromatography (HiTrap Protein G HP column; Amersham Bioscience, Piscataway, N.J., USA) and formulated in PBS.
- mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and an incision was made through the abdominal wall to expose the mesentery and mesenteric venule of 25 to 30- ⁇ m diameter was studied. Exposed mesentery was kept moist by periodic superfusion using PBS (without Ca 2+ or Mg 2+ ) warmed to 37° C.
- the mesentery was transluminated with a 12 V, 100W, DC-stabilized source.
- the shear rate was calculated using an optical Doppler velocity meter as described in Frenette P S, Moyna C, Hartwell D W, Lowe J B, Hynes R O, Wagner D D. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998;91:1318-1324.
- Venule was visualized using a Zeiss (Germany) Axiovert 135 inverted microscope (Objective 10X and 32X) connected to an SVHS video recorder (AG-6730; Panasonic, Tokyo, Japan).
- One venule was chosen per mouse and filmed for 3 min for the baseline before the A23187 superfusion (30 ⁇ l of a 10 Mmol/L solution) and monitored for 10 min.
- Intravital microscopy was done as described above except mesenteric venules of 200 to 300- ⁇ m diameters were studied. Fluorescent platelets (1.25 ⁇ 10 9 platelets/kg) were infused through the tail vein. One venule per animal was filmed for 3 minutes for the baseline before the A23187 superfusion (30 ⁇ l of a 10 ⁇ mol/L solution) and filming continued until after the platelet sticking and rolling returned to baseline. Purified rabbit polyclonal anti-human ADAMTS13 antibody (5 mg/kg mouse) was dissolved in PBS. Control rabbit IgG (Sigma, St. Louis, Mo.) was in PBS. 200 ⁇ l of 1 mM histamine (Sigma) was injected i.p. to stimulate the endothelium. 100 ⁇ l (0.2 mg/ml) of Rhodamine 6G (Sigma) was injected i.v. to label the endogenous platelets and leukocytes prior to surgery and imaging.
- mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and fluorescent platelets (1.25 ⁇ 10 9 platelets/kg) were infused through the retro-orbital plexus of the eye.
- An incision was made through the abdominal wall to expose the mesentery and arterioles of approx. 100 ⁇ m diameters were studied.
- Exposed mesentery was kept moist by periodic superfusion using PBS (without Ca 2+ or Mg 2+ ) warmed to 37° C. The mesentery was transluminated and the shear rate was calculated as described above.
- Arterioles were visualized using the same microscope described above, equipped with a 100-W HBO fluorescent lamp source (Optic Quip, Highland Mills, N.Y.) with a narrow band fluorescein isothiocyanate filter set (Chroma Technology, Brattleboro, Vt.) and a silicon-intensified tube camera C2400 (Hamamatsu, Tokyo, Japan). Whatman paper saturated with ferric chloride ( 10 %) solution was applied topically which induced vessel injury and denudation of the endothelium. The paper was removed after 5 min and vessel was monitored for 40 min after injury or until occlusion. One arteriole was chosen per mouse.
- thrombus formation was performed blinded to the genotype.
- the parameters that were applied to describe the characteristics of thrombus formation were: (1) Single platelet-vessel wall interaction within 2-3 min, determined as the number of fluorescent platelets that deposited on the 250 ⁇ m vessel wall (seen on the video monitor) during 1min. (2) The time required for formation of a thrombus larger than 30 ⁇ m. (3) Thrombus stability by determining the number of thrombi of diameter larger than 30 ⁇ m embolizing away from the viewing field before vessel occlusion. (4) Occlusion time of the vessel, that is, time required for blood to stop flowing for 10 sec and (5) site of vessel occlusion, that is, at the site of injury or downstream.
- Recombinant human ADAMTS13 has been obtained by the methods as described in Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz H P, and Scheiflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100(10):3626-3632. Recombinant human ADAMTS 13 protein was dissolved in 150 mmol NaCl/20 mmol Histidin/2% Sucrose/0.05% Crillet 4HP (Tween 80), pH 7.4 (Baxter Bioscience, Vienna, Austria).
- ADAMTS 13 Recombinant human ADAMTS 13 was injected i.v. (3460 U/kg mouse). Levels of human ADAMTS13 antigen were determined by a slight modification of the ELISA method described by Rieger (Rieger M, Kremer Hovinga J A, Konetschny C, Herzog A, Koller L, Weber A, Remuzzi G, Dockal M, Plaimauer B and Scheiflinger F. Relation between ADAMTS13 Activity and ADAMTS13 Antigen Levels in Healthy Donors and Patients with Thrombotic Microangiopathies (TMA).
- TMA Thrombotic Microangiopathies
- Thrombosis and Hemostasis 2006;95(2):212-20) and r-hu ADAMTS13 activity was determined according to Gerritsen (Gerritsen H E, Turecek P L, Schwarz H P, Laemmle B, and Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999;82:1386-1389). 1 U corresponds to the level of ADAMTS13 activity in pooled normal human plasma.
- vWF von Willebrand factor
- Recombinant mouse ADAMTS13 has been obtained by the methods as described in Bruno K, Volkel D, Plaimauer B, Antoine G, Pable S, Housing D G, Lemmerhirt H L, Dorner F, Zimmermann K, and Scheiflinger F. Cloning, expression and functional characterization of the full-length murine ADAMTS-13. J Thromb Haemost 2005;3(5):1064-1073. Recombinant mouse ADAMTS 13 protein was dissolved in 150 mmol NaCl/20 mmol Histidin/2% Sucrose/0.05% Crillet 4HP (Tween 80), pH 7.4 (Baxter Bioscience, Vienna, Austria).
- Platelet poor whole blood was reconstituted with labeled platelets before perfusion in a parallel-plate flow chamber system coated with 100 m/mL collagen Horm (NYCOMED, Munich, Germany) for 1 h at RT. Where indicated, samples were pretreated with 30 ⁇ g/ml JON/A (emfret Analytics, Wuerzburg, Germany) for 10 min prior to perfusion. Platelet adhesion was visualized with an Axiovert 135 inverted microscope (Zeiss). The percentage of surface area covered by fluorescent platelets was analyzed using NIH Image 1.61 software by an individual blinded to genotypes.
- Results are reported as the mean ⁇ SEM. The statistical significance of the difference between means was assessed by the Student's t test.
- the experimental results have defined a key role for ADAMTS13 in preventing thrombi formation in activated microvenules and excessive thrombus formation in the injured arterioles of mice.
- activating venules 25-30 ⁇ m results in platelet aggregation leading to microthrombi formation ( FIG. 1 ).
- Microthrombi do not form in the venules of WT mice treated identically. When released from the activated endothelium, these microthrombi can travel downstream and cause occlusion elsewhere in the small capillaries where they cannot pass, thus leading to organ ischemia.
- TTP patients suffering from TTP often have microthrombi that are formed in the microvasculature of organs: like brain, heart, pancreas, spleen, kidney and mesentery.
- Various agents including viruses, bacterial shiga toxins, drugs such as ticlopidine and clopidogrel, antibodies and immune complexes can trigger vascular activation perhaps inducing Weibel-Palade body release.
- arterioles which have higher shear stress
- no thrombi could be seen. This is because either Weibel-Palade bodies were not released in these vessels or, more likely, vWF is washed too quickly from the endothelial surface to promote platelet adhesion.
- Platelet strings and aggregates were frequently seen in the Adamts13 ⁇ / ⁇ mice when challenged with Weibel-Palade body secretagogues such as histamine, inflammatory cytokine TNF- ⁇ and activated platelets.
- Weibel-Palade body secretagogues such as histamine, inflammatory cytokine TNF- ⁇ and activated platelets.
- Infusion of the r-hu ADAMTS13 protein in the Adamts13 ⁇ / ⁇ mice challenged with histamine inhibits the platelet strings formation. These strings are cleaved at the upstream end.
- microvenules 25 to 30 ⁇ m
- A23187 Activation of microvenules (25 to 30 ⁇ m) with A23187 results in platelet aggregates leading to thrombi formation in the Adamts13 WT mice infused with anti-ADAMTS13-Ab ( FIG. 3 ).
- these thrombi embolized rapidly, similar to those in the Adamts13 ⁇ / 31 mice.
- Microthrombi formation can be also induced in the WT mice on a C57BL/6 background infused with inhibitory antibody.
- the mouse infused with anti-ADAMTS 13 Ab is in many aspects a good model for acquired TTP.
- it demonstrates the role of the ADAMTS13 in preventing platelet aggregation in the circulation.
- vWF through its receptors, GPIb ⁇ and ⁇ IIb ⁇ 3, contributes to platelet function in initiating platelet aggregation and progression of thrombus formation.
- ADAMTS13 Since early platelet deposition in arterioles is vWF dependent, it means that either plasma ADAMTS13 reduces vWF incorporation into the basement membrane when it is exposed to blood, or that it digests vWF already present in the extra-cellular matrix.
- ADAMTS13 cleavage of VWF domain A2 by ADAMTS13 is facilitated by the binding of VWF to GPIba.
- the VWF-GPIb interaction within the thrombus may negatively regulate thrombus growth.
- Thrombus formation under venous and arterial flow conditions also depends on major integrin ⁇ IIb ⁇ 3.
- the present examples at arteriolar shear rates show that ADAMTS13 modulates the growing thrombus only when platelets in the thrombus express an active beta3 integrin. Under these in vitro and in vivo experimental conditions, ADAMTS13-deficiency did not promote thrombus growth if the major platelet integrin was absent or inhibited ( FIG. 6 ).
- r-hu ADAMTS13 was infused into Adamts13 ⁇ / 31 and WT mice prior to injury.
- the anti-thrombotic effect of the r-hu ADAMTS13 although highly statistically significant, varied among the animals ( FIGS. 7A and 7B ).
- Some mice did not respond to r-hu ADAMTS13 treatment. It is possible that in these mice r-hu ADAMTS13 was proteolytically inactivated by thrombin and plasmin produced at the sites of vascular injury. IL-6 and high amounts of vWF released after inflammation or injury could also reduce ADAMTS13 activity.
- ADAMTS13 have both anti-thrombotic and thrombolytic activity.
- a possible mechanism is ADAMTS13 cleaving the UL-vWF multimers into smaller fragments that are less adhesive or directly cleaving the vWF molecules bridging platelets in a thrombus as is the case in cleavage of platelets attached to strings.
- ADAMTS13 is active at both low venous and high arterial shear stress conditions. It cleaves platelet strings and regulates platelet interaction with the “activated” vessel wall in the venules, prevents thrombi in activated microvenules and modulates the thrombotic response in injured arterioles.
- ADAMTS13 Congenital TTP patients are currently treated by plasma exchange, whereas acquired TTP patients are subjected to plasmapheresis where autoantibodies are removed from the plasma.
- the antithrombotic and thrombolytic effect of ADAMTS13 protein indicates that besides TTP, e.g. recombinant ADAMTS13 can be used to treat patients suffering with thrombotic disorders due to hereditary defects, inflammatory disease, septic conditions, or venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
- the thrombolytic activity of the ADAMTS13 shows that this protein can be used in combination with other therapies to disintegrate thrombi in clogged arteries or after minor stroke.
- the experimental data show that the metalloprotease ADAMTS13 negatively regulates thrombosis, which indicates that the molecule has anti-thrombic activity.
- recombinant human ADAMTS13 protein having thrombolytic activity can be used as a therapeutic agent to treat thrombotic disorders.
Abstract
Description
- This application is a continuation application of U.S. patent application Ser. No. 13/747,307, filed Jan. 22, 2013, which is a divisional application of U.S. patent application Ser. No. 11/454,615, filed Jun. 16, 2006, which claims benefit of U.S. Provisional Patent Application No. 60/691,927, filed Jun. 17, 2005; U.S. patent application Ser. No. 60/729,323, filed Oct. 21, 2005; and U.S. application Ser. No. 60/771,265, filed Feb. 7, 2006; each of which applications is hereby incorporated by references in its entirety for all purposes.
- This invention relates to pharmaceutical compositions having thrombolytic activity comprising a pharmaceutically effective amount of ADAMTS13, to methods of treating or preventing disorders associated with the formation and/or the presence of one or more thrombus as well as to methods for disintegrating one or more thrombus in a patient in need thereof.
- Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
- Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by thrombotic microangiopathy, thrombocytopenia and microvascular thrombosis that can cause various degrees of tissue ischemia and infarction. Clinically, TTP patients are diagnosed by symptoms such as thrombocytopenia, schistocytes (fragments of erythrocytes) and elevated levels of lactate dehydrogenase (Moake J L. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600; Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004;41:4-14; Sadler J E, Moake J L, Miyata T, George J N. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program). 2004:407-423; Sadler J E. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191). In 1982, Moake et al. found unusually large von Willebrand factor (UL-vWF) multimers in the plasma of the patients with chronic relapsing TTP (Moake J L, Rudy C K, Troll J H, Weinstein M J, Colannino N M, Azocar J, Seder R H, Hong S L, Deykin D. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435). The link between UL-vWF and TTP gained support with independent findings by Furlan et al. and Tsai and Lian that most patients suffering from TTP are deficient in a plasma metalloprotease that cleaves vWF (Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Laemmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103; Tsai H M, Sussman, II, Ginsburg D, Lankhof H, Sixma J J, Nagel R L. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997;89:1954-1962; Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594). The protease belongs to the ADAMTS family and is designated as ADAMTS13 (A Disintegrin-like And Metalloprotease with Thrombospondin type I repeats), a 190 kDa glycosylated protein produced predominantly by the liver (Levy G G, Nichols W C, Lian E C, Foroud T, McClintick J N, McGee B M, Yang A Y, Siemieniak D R, Stark K R, Gruppo R, Sarode R, Shurin S B, Chandrasekaran V, Stabler S P, Sabio H, Bouhassira E E, Upshaw J D, Jr., Ginsburg D, Tsai H M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494; Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666; Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063; Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo). 2001;130:475-480; Gerritsen H E, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654-1661). Mutations in the ADAMTS13 gene have been shown to cause TTP (Levy G G, Nichols W C, Lian E C, Foroud T, McClintick J N, McGee B M, Yang A Y, Siemieniak D R, Stark K R, Gruppo R, Sarode R, Shurin S B, Chandrasekaran V, Stabler S P, Sabio H, Bouhassira E E, Upshaw J D, Jr., Ginsburg D, Tsai H M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494). Idiopathic TTP, often caused by autoantibodies inhibiting ADAMTS-13 activity, is a more common disorder that occurs in adults and older children and can recur at regular intervals in 11-36% of patients (Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594; Furlan M, Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol. 1998;11:509-514). Non neutralizing autoantibodies could also inhibit ADAMTS activity by inducing clearance from circulation (Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241 -3243). Plasma ADAMTS13 activity in healthy adults ranges from 50% to 178% (Moake J L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med. 2002;126:1430-1433). In most patients with familial or acquired TTP, plasma ADAMTS13 activity is absent or less than 5% of the normal. Without treatment the mortality rate exceeds 90%, but plasma therapy has reduced mortality to about 20% (Moake J L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med. 2002;126:1430-1433).
- vWF synthesized in megakaryocytes and endothelial cells is stored in platelet α-granules and Weibel-Palade bodies, respectively, as ultra large vWF (UL-vWF) 5. Moake J L, Rudy C K, Troll J H, Weinstein M J, Colannino N M, Azocar J, Seder R H, Hong S L, Deykin D. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435; Wagner D D, Olmsted J B, Marder V J. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982;95:355-360; Wagner D D, Bonfanti R. von Willebrand factor and the endothelium. Mayo Clin Proc. 1991;66:621-627; Sporn L A, Marder V J, Wagner D D. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood. 1987;69:1531-1534; Tsai H M, Nagel R L, Hatcher V B, Sussman, II. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun. 1989;158:980-985; Tsai H M, Nagel R L, Hatcher V B, Sussman, II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989;73:2074-2076). Once secreted from endothelial cells, these UL-vWF multimers are cleaved by ADAMTS13 in circulation into a series of smaller multimers at specific cleavage sites within the vWF molecule (Tsai H M, Nagel R L, Hatcher V B, Sussman, II. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun. 1989;158:980-985; Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88:774-782; Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lammle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA. 1993;90:7503-7507). The protease cleaves at the Tyr842-Met843 bond in the central A2 domain of the mature vWF subunit and requires zinc or calcium for activity (Dent J A, Berkowitz S D, Ware J, Kasper C K, Ruggeri Z M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA. 1990;87:6306-6310). vWF exists in “ball-of-yarn” and filamentous form as seen by electron microscopy (Slayter H, Loscalzo J, Bockenstedt P, Handin R I. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. J Biol Chem. 1985;260:8559-8563). Furthermore, atomic force microscopy confirms that vWF exits in a globular conformation under static conditions and an unfolded filamentous state after exposure to shear stress (Siedlecki C A, Lestini B J, Kottke-Marchant K K, Eppell S J, Wilson D L, Marchant R E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939-2950). This could occur also in vivo when one end of the vWF filament is anchored to a surface.
- UL-vWF multimers, present in Weibel-Palade bodies, when released by activated endothelial cells bind platelets more tightly (through GPIbα) than plasma vWF (27. Arya M, Anvari B, Romo G M, Cruz M A, Dong J F, McIntire L V, Moake J L, Lopez J A. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99:3971-397). It was demonstrated in vitro that the platelets align as beads on the released UL-vWF on the endothelial surface (Dong J F, Moake J L, Nolasco L, Bernardo A, Arceneaux W, Shrimpton C N, Schade A J, McIntire L V, Fujikawa K, Lopez J A. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039). These UL-vWF secreted multimers are anchored to the cell surface as long stringlike structures. These multimers are then cleaved by ADAMTS13 as they are secreted from stimulated endothelial cells (Dong J F, Moake J L, Bernardo A, Fujikawa K, Ball C, Nolasco L, Lopez J A, Cruz M A. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639).
- Thrombi of TTP patients consist of little fibrin and mainly of vWF and platelets, suggesting vWF-mediated platelet aggregation as a cause of thrombosis (30. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38:469-479). Patients with relapsing TTP have ultra-large multimers in the plasma. The UL-vWF multimers accumulate over time because the persistence of the inhibitor (Anti-ADAMTS13 Ab) decreases ADAMTS13 activity. The UL-vWF multimers are hyperactive and unfold as a result of shear stress causing platelet aggregation, resulting in intravascular thrombosis (Tsai H M. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med. 2002;80:639-647; Tsai H M. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. J Thromb Haemost. 2003;1:2038-2040; discussion 2040-2035).
- It is believed that the presence of hyper-reactive UL-vWF multimers in the plasma due to ADAMTS13 deficiency could be associated with an increased risk of arterial thrombosis linked to coronary heart disease.
- Therefore, a strong need exists for providing new compositions which are capable of preventing and/or treating thrombi caused by certain disorders in a patient.
- An object of the present invention is to provide a pharmaceutical composition having thrombolytic activity. The pharmaceutical composition comprises a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof, and optionally one or more pharmaceutically acceptable carrier and/or diluent. Said composition may also comprise one or more additional active ingredient. Further, the present invention relates to a method of treating or preventing a disorder associated with the formation and/or presence of one or more thrombus and to a method of disintegrating one or more thrombus in a patient in need thereof. Examples of disorders associated with the formation and/or the presence of one or more thrombus are hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, and disseminated intravascular coagulation (DIC). Accordingly, a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof can be used for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof. Said pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof may range, for example, from 0.1 to 20 mg/kg body weight.
-
FIG. 1 . Thrombus formation in microvenules. Mesenteric venules of approx. 25-30 μm in diameter were visualized after an incision was made through the abdominal wall to expose the mesentery of live mice. One min after topical superfusion of A23187, thrombus formation was observed in Adamts13 −/−mice (n=5). The arrows indicate the microthrombi. No microthrombi formation was observed in WT mice treated identically (n=5). Thus, stimulation of Weibel-Palade body secretion can lead to spontaneous thrombus formation in Adamts13−/−mice in the absence of vascular injury. -
FIG. 2 . ADAMTS13 inhibitor increases platelets adhesion and string formation to vessel wall. Fluorescently-labeled platelets representing approx. 2.5% of total platelets were observed in mesenteric venules (200-250 μm) of live mice before (baseline) and after A23187 superfusion. A: Platelets began to adhere to theendothelium 30 to 45 seconds after superfusion. In WT (infused with anti-human ADAMTS13 Ab) mice (n=4) more platelets adhered to vessel wall after 4 min compared to WT (infused with PBS) control (n=4). Arrowheads indicate the 20 μm strings of platelets attached at one end to endothelium and waving in blood stream. Inset time points in lower right corner refer to the time after superfusion of A23187. Bar shown in the middle panel is (approx.) 50 μm. B: In 5 out of 7 WT mice infused with inhibitor to ADAMTS13 an approx. 25-35 μm long platelets string anchored to the vessel wall for up to 10 sec. Inset time points in lower right corner refer to the time after superfusion of A23187. Bar shown in the middle panel is (approx.) 25 μm. -
FIG. 3 . Thrombus formation in microvenules of WT mice infused with ADAMTS13 Inhibitor. Mesenteric venules of approx 25-30 μm in diameter were observed. One min after topical superfusion with A23187, thrombus formation was observed in 4 out of 6 Adamts13 WT mice infused with ADAMTS13 inhibitor. The microthrombi formation was similar to that seen in Adamts13−/−mice (FIG. 1 ). Arrowheads indicate microthrombi. The microthrombi did not form in WT mice infused with PBS (n=5). -
FIG. 4 . Recombinant ADAMTS13 inhibits platelet strings in Adamts13−/−mice. Rhodamin 6G was used to label endogenous platelets and leukocytes. 1 mM histamine (200 μl) was administered i.p. 15 mins before surgery and 3 mesenteric venules of approx. 200-300 m in diameter were visualized per mouse. A: No platelet strings are seen in Adamts13 WT mice (n=5). B: Platelet strings (indicated by arrowheads) are seen in the Adamts13 −/−mice (n=5). C: The platelet strings could form platelet aggregates in Adamts13 −/−mice as indicated by arrowhead. D: Infusion of recombinant human ADAMTS13 protein inhibits the platelets strings in Adamts13 −/−mice (n=4). -
FIG. 5 . Quantitative analysis of platelet adhesion and thrombi formation in arterioles of WT andAdamts 13 −/−mice. A: The number of fluorescent platelets deposited per minute was determined in the interval 2-3 min after injury (total number of adherent platelets counted in 1 min interval). For statistics and mean, platelets greater than 100 was considered as 100. Absence of ADAMTS13 in the plasma clearly influences the early platelet interaction with the subendothelium. Compared with WT, inAdamts 13 −/−more platelets were deposited on the vessel wall (P<0.05). B: Thrombus (>30 μm) appeared sooner after injury in Adamts13−/−mice (mean=6.64±0.93) compared with WT (mean=10.78±0.80) and this was statistically significant (P<0.005). This demonstrates that cleavage of UL-vWF multimers by ADAMTS13 delays thrombus formation. C: The occlusion time when blood flow completely stopped for 10 sec was determined. Both WT and Adamts13−/−mice occluded at the site of injury; however in Adamts13−/−mice occlusion time was shorter (mean=10.56 35 0.72) as compared with WT (mean=16.69±1.25 minutes). The difference was highly statistically significant (P<0.0005). D: Fluorescently-labeled platelets representing approx. 2.5% of total platelets were observed in mesenteric arterioles of live mice after ferric chloride injury. Blood flow was from left to right. Inset time points in lower right corner refer to the time after injury. Single adherent platelets are seen in the arteriole at 4 min after injury in the WT, whereas a thrombus (approx. 30 μm) can already be seen in the Adamts13−/31 mouse arteriole at the same time point. The vessel was occluded at 10 min by a thrombus at the site of injury in Adamts13−/31 mice, while the WT mouse arteriole remained opened at that time. Photographs are representative of 10 mice of each genotype. -
FIG. 6 . Inhibition of integrin αIIbβ3 blocks thrombus formation of ADAMTS13−/31 platelets on collagen under arterial shear rate conditions. Adamts13+/+ or Adamts13−/−whole blood was perfused for 2 min over a collagen surface at a shear rate of 1500s-1. A: Representative images are shown. Upper panels-untreated whole blood, lower panels-pretreated with blocking antibody against αIIbβ3 (JON/A). B: Quantification of the surface area covered by platelets after 2 min of perfusion. Four frames from different areas of the flow chamber were analyzed for each blood sample. Data represent the mean percentage of surface area covered by fluorescent platelets ±SEM (n=3-4). -
FIG. 7 . Infusion of recombinant human ADAMTS13 inhibits thrombus growth. Recombinant human ADAMTS13 was infused (i.v.) in the Adamts13−/−mice 15 min before the ferric chloride injury. The occlusion time (blood flow completely stopped for 10 sec) was determined. A: Five out of 13 Adamts13−/−mice, infused with recombinant human ADAMTS13 did not occlude in the arteriole at up to 40 min of observation time (mean occlusion time=23.80±3.71 min), whereas, all 10 Adamts13−/−mice infused with recombinant buffer only occluded (mean occlusion time=11.17±0.87); (P=0.005). B: Occlusion time in injured arterioles of WT (C57BI/6J) mice infused either with r-hu ADAMTS13 (mean occlusion time=27.99±4.72 min) or buffer alone (mean occlusion time=13.12±0.55 min). C: Representative fluorescent images of injured arteriole of an Adamts13−/−mouse treated with r-hu ADAMTS13 are shown. Arrowheads indicate a disintegrating thrombus. -
FIG. 8 . Infusion of recombinant mouse ADAMTS13 inhibits thrombus growth in WT mice. Recombinant mouse ADAMTS13 (2.6 mg/kg mouse) was infused (i.v.) into theWT mice 5 min before the ferric chloride injury. Four out of nine WT mice infused with recombinant mouse ADAMTS13 did not occlude the injured arterioles at 40 min of observation time (mean occlusion time=27.04±3.84 min), whereas all WT mice infused with buffer occluded (mean occlusion time=15.15±1.18 min, P=0.006). -
FIG. 9 . Table 1: Hemodynamic parameters prior to and after application of A23187 on venules (FIG. 1 ); Table 2: Hemodynamic parameters prior to and after application of ferric chloride on arterioles (FIG. 5 ). - One aspect of the present invention relates to a pharmaceutical composition having thrombolytic activity, comprising a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof.
- The term “thrombolytic activity” as used herein means the disintegration of one or more thrombus. Suitable methods for the determination of thrombolytic activity are well known in the art. For example, suitable methods are the determination of the lysis of a whole blood clot using tPA or streptokinase, or the determination of the thrombus lysis in vivo.
- The term “disintegration” as used herein includes the partial or complete disintegration, dissolving, dissolution, destruction and/or lysis of a thrombus.
- The term “thrombus” as used herein comprises a blood clot, especially a platelet-comprising blood clot, a microthrombus, and/or an embolus. Said thrombus may be attached to an arterial or venous blood vessel or not, and may partially or completely block the blood flow in an arterial or venous blood vessel.
- The term “biologically active derivative” as used herein means any polypeptides with substantially the same biological function as ADAMTS13. The polypeptide sequences of the biologically active derivatives may comprise deletions, additions and/or substitution of one or more amino acids whose absence, presence and/or substitution, respectively, do not have any substantial negative impact on the biological activity of polypeptide. The biological activity of said polypeptides may be measured, for example, by the reduction or delay of platelet adhesion to the endothelium, the reduction or delay of platelet aggregation, the reduction or delay of the formation of platelet strings, the reduction or delay of thrombus formation, the reduction or delay of thrombus growth, the reduction or delay of vessel occlusion, the proteolytical cleavage of vWF, and/or the disintegration of thrombi.
- The terms “ADAMTS13” and “biologically active derivative”, respectively, also include polypeptides obtained via recombinant DNA technology. The recombinant ADAMTS13 (“rADAMTS13”), e.g. recombinant human ADAMTS13 (“r-hu-ADAMTS13”), may be produced by any method known in the art. One specific example is disclosed in WO 02/42441 which is incorporated herein by reference with respect to the method of producing recombinant ADAMTS13. This may include any method known in the art for (i) the production of recombinant DNA by genetic engineering, e.g. via reverse transcription of RNA and/or amplification of DNA, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by transfection, i.e. via electroporation or microinjection, (iii) cultivating said transformed cells, e.g. in a continous or batchwise manner, (iv) expressing ADAMTS13, e.g. constitutively or upon induction, and (v) isolating said ADAMTS13, e.g. from the culture medium or by harvesting the transformed cells, in order to (vi) obtain substantially purified recombinant ADAMTS13, e.g. via anion exchange chromatography or affinity chromatography. The term “biologically active derivative” includes also chimeric molecules such as e.g. ADAMTS13 (or a biologically active derivative thereof) in combination with Ig, in order to improve the biological/pharmacological properties such as e.g. half life of ADAMTS13 in the circulation system of a mammal, particularly human. The Ig could have also the site of binding to an optionally mutated Fc receptor.
- The rADAMTS13 can be produced by expression in a suitable prokaryotic or eukaryotic host system characterized by producing a pharmacologically effective ADAMTS13 molecule. Examples of eukaryotic cells are mammalian cells, such as CHO, COS, HEK 293, BHK, SK-Hep, and HepG2. There is no particular limitation to the reagents or conditions used for producing or isolating ADAMTS13 according to the present invention and any system known in the art or commercially available can be employed. In one embodiment of the present invention rADAMTS13 is obtained by methods as described in the state of the art.
- A wide variety of vectors can be used for the preparation of the rADAMTS13 and can be selected from eukaryotic and prokaryotic expression vectors. Examples of vectors for prokaryotic expression include plasmids such as pRSET, pET, pBAD, etc., wherein the promoters used in prokaryotic expression vectors include lac, trc, trp, recA, araBAD, etc. Examples of vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as pAO, pPIC, pYES, pMET, using promoters such as AOX1, GAP, GAL1, AUG1, etc; (ii) for expression in insect cells, vectors such as pMT, pAc5, pIB, pMIB, pBAC, etc., using promoters such as PH, p10, MT, Ac5, OpIE2, gp64, polh, etc., and (iii) for expression in mammalian cells, vectors such as pSVL, pCMV, pRc/RSV, pcDNA3, pBPV, etc., and vectors derived form viral systems such as vaccinia virus, adeno-associated viruses, herpes viruses, retroviruses, etc., using promoters such as CMV, SV40, EF-1, UbC, RSV, ADV, BPV, and β-actin.
- Optionally, the pharmaceutical composition of the present invention also comprises one or more pharmaceutically acceptable carrier and/or diluent.
- The pharmaceutical composition of the present invention may also comprise one or more additional active ingredients such as e.g. anti-thrombotic agents, agents that stimulate ADAMTS13 production/secretion by the treated patient/individual, agents that inhibit the degradation of ADAMTS13 and thus prolonging its half life, agents that enhance ADAMTS13 activity (for example by binding to ADAMTS13, thereby inducing an activating conformational change), or agents that inhibit ADAMTS13 clearance from circulation, thereby increasing its plasma concentration. Examples of anti-thrombotic agents include anti-platelets, t-PA, aspirin and heparin.
- The present invention further relates to a method of treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus, comprising the step of administering a composition according to the invention to a patient. Said disorder may be due to hereditary defects, inflammatory diseases, stroke or septic conditions. Examples of disorders associated with the formation and/or the presence of one or more thrombus are hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, disseminated intravascular coagulation (DIC), and venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
- Another aspect of the present invention relates to a method of disintegrating one or more thrombus in a patient, comprising the step of administering a composition according to the present invention to said patient.
- The route of administration of the composition of the present invention does not exhibit a specific limitation and can be, for example, subcutaneous or intravenous. The term “patient” as used in the present invention includes mammals, particularly human.
- Furthermore, the present invention relates to the use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus.
- Another aspect of the present invention is the use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of a pharmaceutical composition for disintegrating one or more thrombus in a patient in need thereof.
- The pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof may range, for example, from 0.1 to 20 mg/kg body weight.
- The present invention will be further illustrated in the following examples, without any limitation thereto.
- Example 1: Endothelial activation results in thrombi formation in microvenules of Adamts 13−/−mice
- More platelet sticking/translocating in venules (200-250 μm) activated with calcium ionophore A23187 (a secretagouge of Weibel-Palade bodies) at low shear rate (approx. 100 s−1) in Adamts13−/31 mice has been observed compared with WT. It was investigated whether activation of microvenule endothelium by A23187 could result in platelet aggregation resulting in thrombus formation. A23187 does not denude the endothelium (Andre P, Denis C V, Ware J, Saffaripour S, Hynes R O, Ruggeri Z M, Wagner D D. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322-3328). The shear rate (200-250 s−1) and diameter of all the venules (25-30 μm) studied were similar for Adamts13−/31 and WT mice (Table 1). In the microvenules of Adamts13−/−mice, 45 sec to 1 min after topical superfusion of A23187, platelet aggregation resulted in thrombus formation was observed (
FIG. 1 ). The thrombi were unstable and flushed away in the blood stream leading to frequent embolization causing downstream occlusion. However, the occlusion lasted only 3-4 seconds and the venule reopened afterwards. Thrombus formation was no longer seen at the site ofstimulation 2 min after A23187 superfusion. In WT mice treated identically, strings of platelets and very small platelet aggregates could be seen attached to the endothelium for 1 sec, but this did not result in thrombus formation. Arterioles running parallel to the venules in Adamts13−/31 or WT mice did not show any platelet aggregation or thrombus formation. No platelet strings could be observed in the arterioles. These observations demonstrate that ADAMTS13 inhibits platelet aggregation and thus prevents thrombus formation in the microvenules. - Example 2: An antibody to ADAMTS13 induces formation of platelets strings in venules of WT mice.
- Previous studies have shown that most patients suffering from the acquired form of TTP have autoimmune inhibitors to ADAMTS13 (Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594; Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle P A, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584). Polyclonal anti-human ADAMTS13 Ab (dissolved in PBS) was infused in
WT mice 2 hr before the surgery. After topical superfusion of A23187 of both control mice (infused with PBS) and mice infused with Anti-ADAMTS13 Ab, many platelets stuck/translocated on the endothelium, reaching a peak of platelet adhesion between 45 sec to 1 min that progressively decreased with time. However, more platelet sticking was observed 4 min after the A23187 application in the Ab-infused WT as compared with control (FIG. 2A ). The phenomenon observed was similar to Adamts13−/31 . Strings of platelets varying from 20-40 μm attached at one end to the endothelium and waving in the blood stream were observed. Strings of platelets were either not seen or were very short lived (less than 2 sec) in the mice injected with PBS or control Ig. In WT mice on a genetic background marked by elevated vWF levels (CASA/Rk), treated with inhibitory antibody, the strings of platelets were even longer (varying from 30-60 μm) indicating that these were formed primarily by vWF polymers. (In some mice, these platelet strings anchored to the endothelium for up to 10 sec (FIG. 2B ) and then were washed away.) - Example 3: ADAMTS13 inhibitor results in thrombi formation in microvenules in WT mice
- In WT mice, infused with anti-human ADAMTS13-
Ab 2 hours before surgical preparation, microthrombi formed on the vessel wall 45 sec to 1 min after topical superfusion of A23187 in 4 out of 6 mice (FIG. 3 ). The microthrombi appearance were similar to those seen in the Adamts13−/31 mice (FIG. 1 ). Then, the inhibitory antibody was infused in the WT mice on a C57BL/6 background. In three out of 5 mice microthrombi formed. In control WT mice, minute platelet aggregates could be seen attached to the endothelium but did not result in thrombus formation (n=3). - Example 4: Histamine induces platelets strings in the venules of Adamts13−/−mice, whereas, recombinant ADAMTS13 inhibits the formation
- Histamine produced during inflammation is a secretagouge of Weibel-Palade bodies and stimulates the endothelium. Endogenous platelets were labeled by infusing Rhodamine 6G i.v. prior to surgery. One mM (200 μl) histamine was injected i.p. 15 min before the surgical preparation in the Adamts13−/31 (n=5) and WT (n=5) mice and venules at a shear rate of approx. 100 s−1 were visualized. In the WT, strings of platelets were not seen or were short lived (less than 5 sec,
FIG. 4A ), whereas in the Adamts13−/31 platelet strings varying from 20-100 μm could be seen (FIG. 4B ) anchored to the endothelium for about a minute. In some mice, the platelet strings anchored to the endothelium from 2 to 5 min. Some strings appeared to coalesce forming aggregates (FIG. 4C ) that were later released into the blood stream. Infusion of recombinant human ADAMTS13 (r-hu ADAMTS13) protein in the Adamts13−/31 mice (n=4, 3 venules per mouse) inhibited platelet strings in all the 12 venules examined (FIG. 4D ), thus demonstrating the activity of ADAMTS13 at low shear. - Example 5: Platelet binding to sub endothelium is increased in Adamts13−/−mice
- Ferric chloride (FeCl3) injury leads to deendothelization and exposes sub endothelium (Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392). Platelet subendothelial interactions after injury at arterial shear are initiated by GPIb-vWF interaction and then propagated by other receptors (Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392). In both WT and Adamts13−/31 mice, platelet-vessel wall interaction started rapidly after ferric chloride application to the arteriole. The number of animals in which more than 100 platelets were deposited 2-3 min after injury was higher in Adamts13−/31 mice (
FIG. 5A ). In the Adamts13−/31 , 7 out of 12 mice showed greater than 100 platelets deposited on the vessel wall, compared to 3 of 10 in the WT mice. The results were statistically significant (P<0.05,FIG. 5A ). - Example 6: Accelerated thrombus formation in injured arterioles of Adamts13−/−mice
- vWF present in the plasma is either constitutively synthesized by endothelial cells or is secreted in the form of unusually large multimers from the platelet a-granules and endothelial Weibel-Palade bodies upon activation. UL-vWF is the most adhesive and reactive form of vWF and may lead to platelet aggregation resulting in a thrombus if not processed by ADAMTS13. In the ferric chloride thrombosis model in the Adamts13−/31 mice, thrombi grew faster as thrombi greater than 30 μm were seen at 6.64±0.93 min compared to 10.78±0.80 min in the WT mice and the results were statistically significant (P<0.005,
FIG. 5B ). The thrombi grew to occlusive size in 10.56±0.72 min in Adamts13−/31 , whereas in WT still the vessels were open (P<0.0005,FIGS. 5C and 5D ). In the WT, the mean vessel occlusion time was 16.69±1.25 after injury (P<0.0005). All the vessels occluded at the site of injury. The shear rate and diameter of arterioles studied were similar for Adamts13−/− and WT mice (Table 2). Of note, in arterioles of Adamts13−/31 mice the mean time for formation of thrombus (>30 μm) as well as mean occlusion time were less than for any individual WT mouse (FIGS. 5B and 5C ). It has been observed that emboli (>30 μm) formed in 4 out of 10 (40%) Adamts13−/−mice whereas only in 2 of 11 (18.2%) WT mice showed embolization. Thus the Adamts13−/− thrombi appeared slightly less stable than WT. The observed embolization in Adamts13−/31 mice did not lead to downstream occlusion. - Example 7: ADAMTS13-deficiency enhances thrombus growth in a αIIbβ3 integrin-dependent manner
- In vitro flow chamber studies were performed with whole blood in the presence or absence of a blocking antibody (JON/A) against αIIβ3 (Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry 2002;48:80-86) (
FIG. 6 ). To quantify the size of the thrombi, the surface area covered by fluorescently-labeled platelets was determined. Adamts13−/−blood formed significantly larger thrombi than WT when perfused over collagen for 2 minutes at a shear rate of 1500 s-1 (44.66±3.63% vs. 20.22±3.88%, P<0.0005), demonstrating again the key role of ADAMTS13 in limiting thrombus growth. In the presence of the blocking antibody to αIIbβ3, only single platelets adhered to the collagen surface and thrombus formation was completely inhibited in both the WT and Adamts13−/−blood (3.01±0.97% vs. 2.82±0.39%, P>0.05). In addition, it was tested whether infusion of ADAMTS13 inhibitory antibody into beta3 integrin-deficient mice (Hodivala-Dilke K M, McHugh K P, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross F P, Coller B S, Teitelbaum S, Hynes R O. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival J Clin Invest 1999;103:229-238) would induce thrombus formation after ferric chloride injury. In injured arterioles of beta3−/−mice (3 animals were evaluated) no thrombi could be detected despite the presence of the anti-ADAMTS13 antibody (not shown). Taken together these results indicate that, at the arterial shear rates, ultralarge vWF enhances thrombus growth in a αIIbβ3-dependent manner. - Example 8: Infusion of recombinant human ADAMTS13 in Adamts13−/− or WT (C57BL/6J) mice inhibits thrombus growth by destabilizing the platelet aggregate or thrombus
- Cleavage of the vWF subunit into proteolytic fragments by recombinant human ADAMTS13 (r-hu ADAMTS13) has been shown in vitro (Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz H P, Scheiflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626-3632). It has been demonstrated that r-hu ADAMTS13 corrects the vWF cleavage defect in hereditary TTP plasma (Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt J D, Laemmle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura. Br J Haematol 2003;120:821-824). Since accelerated growth of thrombi in Adamts13−/−mice has been observed, it is hypothesized that ADAMTS13 negatively modulates thrombus growth and therefore infusion of r-hu ADAMTS-13 in Adamts13−/−mice could delay thrombus formation. The concentration of the circulating human protein was approximately 8.8 U/ml 17 min after infusion and 1.1 U/ml 53 min after infusion of r-hu ADAMTS13 into Adamts13−/−mice. These times correspond approximately to the onset of ferric chloride injury and the termination of the experiment. In 5 out of 13 Adamts13−/−mice infused with r-hu ADAMTS13, injured arterioles did not occlude for up to 40 min when the experiment was terminated (
FIG. 7A ). The effect of the infused r-hu ADAMTS13 was more than that of endogenous ADAMTS13 in WT mice as in this injury model all WT vessels occluded at less than 24 min (FIG. 5C ). The mean occlusion time was significantly prolonged in comparison with the control mice infused with buffer (P<0.0005). In all mice whose arterioles did not occlude, thrombi did form but were unstable and disintegrated (FIG. 7C ). This phenomenon of thrombi formation and disintegration was present during the entire period of observation. The infusion of r-hu ADAMTS13 prior to injury in WT mice (C57BI/6J) caused significant delay in occlusion time with half of the arterioles not occluding by 40 min while all arterioles of WT mice infused with vehicle occluded by 15 min (FIG. 7B , P<0.008). Thus, ADAMTS13 appears to have a significant anti-thrombotic potential even in WT mice with normal levels of endogenous ADAMTS13 protein. - Example 9: Infusion of recombinant mouse ADAMTS13 inhibits thrombus growth in WT mice
- r-mouse ADAMTS13 (2.6 mg/kg mouse) was infused (i.v.) into the
WT mice 5 min before the ferric chloride injury. A previously described model was used with slight modifications as described below.FIG. 8 shows that four out of nine WT mice infused with r-ADAMTS13 did not occlude the injured arterioles at 40 min of observation time (mean occlusion time=27.04±3.84 min), whereas all WT mice infused with buffer occluded (mean occlusion time=15.15±1.18 min, P=0.006). Western analysis of the plasma samples taken at the end of the experiment showed that the shorter occlusion time in some of the mice infused with r-ADAMTS13 (similar to WT) was due to increased clearance of the recombinant protein. - Thus, mouse ADAMTS13 appears to have the same anti-thrombotic potential as the human ADAMTS13 in WT mice with normal levels of endogenous ADAMTS protein.
- These results show that ADAMTS13 has an antithrombotic as well as thrombolytic activity.
- Experimental Procedures
- Animals
- Mice used in the examples were siblings obtained from crosses of Adamts13+/−mice on C57BL/6J/129Sv background (Motto D G, Chauhan A K, Zhu G, Homeister J, Lamb C B, Desch K C, Zhang W, Tsai H M, Wagner D D, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115:2752-2761). The mice of pure C57BI/6J background were purchased from the Jackson Laboratory, Bar Harbor, Me. and beta3 integrin −/31 mice on Balb/C bacjground were a gift from Richard Hynes (MIT). The mice used for intravital microscopy were young mice (approx. 4 weeks old), both male and female, weighing 14 to 18 grams. Infused platelets were isolated from 4 to 6 months old mice of the same genotype. Animals were bred and housed at CBR Institute for Biomedical Research and all experimental procedures were approved by its Animal Care and Use Committee.
- Materials
- Calcium ionophore A23187 and ferric chloride were from Sigma Chemicals, St. Louis, Mo.
- Blood sampling and platelet preparation
- Blood was harvested from the retro-orbital venous plexus by puncture and collected in 1.5 ml polypropylene tubes comprising 300 μl of heparin (30 U/ml). Platelet rich plasma (PRP) was obtained by centrifugation at 1200 rpm for 5 min. The plasma and buffy coat comprising some RBCs were gently transferred to fresh polypropylene tubes and recentrifuged at 1200 rpm for 5 min. The PRP was transferred to fresh tubes comprising 2 μl of PGI2 (2 μg/ml) and incubated at 37° C. for 5 min. After centrifugation at 2800 rpm, pellets were resuspended in 1 ml modified Tyrode's-HEPES buffer (137 mM NaCl, 0.3 mM Na2HPO4, 2 mM KCl, 12 mM NaHCO3, 5 mM HEPES, 5 mM glucose, 0.35% BSA) comprising 2 μl of PGI2 and incubated at 37° C. for 5 min. The suspended pellet was centrifuged at 2800 rpm for 5 min. In order to remove PGI2, the washing step was repeated twice and platelets were fluorescently labeled with calcein AM 0.25 mg/mL (Molecular Probes, Eugene, Oreg.) for 10 min at room temperature.
- Polyclonal Anti-ADAMTS13 IgG production and purification
- Polyclonal rabbit anti-human ADAMTS13 IgG was produced by Baxter Bioscience, Vienna Austria. The antibody was obtained by immunization of New Zealand white rabbits with purified r-hu ADAMTS13, C-terminally tagged with six His residues. Two rabbits were immunized by injection of 20 μg of r-hu ADAMTS13 (6-His) in 200 μl of complete Freund's adjuvant. The animals were boostered after two, four and six weeks by injecting 20 μg of r-hu ADAMTS13 (6-His) in 200 μl of incomplete Freund's adjuvant. After eight weeks the rabbits were sacrificed and bled. IgG antibodies were purified by Protein G affinity chromatography (HiTrap Protein G HP column; Amersham Bioscience, Piscataway, N.J., USA) and formulated in PBS.
- Thrombosis in microvenules
- Intravital microscopy was as done as described in Frenette P S, Johnson R C, Hynes R O, Wagner D D. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 1995;92:7450-7454. Briefly, mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and an incision was made through the abdominal wall to expose the mesentery and mesenteric venule of 25 to 30-μm diameter was studied. Exposed mesentery was kept moist by periodic superfusion using PBS (without Ca2+ or Mg2+) warmed to 37° C. The mesentery was transluminated with a 12 V, 100W, DC-stabilized source. The shear rate was calculated using an optical Doppler velocity meter as described in Frenette P S, Moyna C, Hartwell D W, Lowe J B, Hynes R O, Wagner D D. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998;91:1318-1324. Venule was visualized using a Zeiss (Germany) Axiovert 135 inverted microscope (Objective 10X and 32X) connected to an SVHS video recorder (AG-6730; Panasonic, Tokyo, Japan). One venule was chosen per mouse and filmed for 3 min for the baseline before the A23187 superfusion (30 μl of a 10 Mmol/L solution) and monitored for 10 min.
- Platelet adhesion in large venules
- Intravital microscopy was done as described above except mesenteric venules of 200 to 300-μm diameters were studied. Fluorescent platelets (1.25×109 platelets/kg) were infused through the tail vein. One venule per animal was filmed for 3 minutes for the baseline before the A23187 superfusion (30 μl of a 10 μmol/L solution) and filming continued until after the platelet sticking and rolling returned to baseline. Purified rabbit polyclonal anti-human ADAMTS13 antibody (5 mg/kg mouse) was dissolved in PBS. Control rabbit IgG (Sigma, St. Louis, Mo.) was in PBS. 200 μl of 1 mM histamine (Sigma) was injected i.p. to stimulate the endothelium. 100 μl (0.2 mg/ml) of Rhodamine 6G (Sigma) was injected i.v. to label the endogenous platelets and leukocytes prior to surgery and imaging.
- Thrombosis in arterioles
- A model described in Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392, was used with slight modifications (Ni H, Denis C V, Subbarao S, Degen J L, Sato T N, Hynes R O, Wagner D D. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392). Briefly, mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and fluorescent platelets (1.25−109 platelets/kg) were infused through the retro-orbital plexus of the eye. An incision was made through the abdominal wall to expose the mesentery and arterioles of approx. 100 μm diameters were studied. Exposed mesentery was kept moist by periodic superfusion using PBS (without Ca2+ or Mg2+) warmed to 37° C. The mesentery was transluminated and the shear rate was calculated as described above. Arterioles were visualized using the same microscope described above, equipped with a 100-W HBO fluorescent lamp source (Optic Quip, Highland Mills, N.Y.) with a narrow band fluorescein isothiocyanate filter set (Chroma Technology, Brattleboro, Vt.) and a silicon-intensified tube camera C2400 (Hamamatsu, Tokyo, Japan). Whatman paper saturated with ferric chloride (10%) solution was applied topically which induced vessel injury and denudation of the endothelium. The paper was removed after 5 min and vessel was monitored for 40 min after injury or until occlusion. One arteriole was chosen per mouse.
- Quantitative Analysis of arteriolar thrombus
- Analysis of the recorded tape was performed blinded to the genotype. The parameters that were applied to describe the characteristics of thrombus formation were: (1) Single platelet-vessel wall interaction within 2-3 min, determined as the number of fluorescent platelets that deposited on the 250 μm vessel wall (seen on the video monitor) during 1min. (2) The time required for formation of a thrombus larger than 30 μm. (3) Thrombus stability by determining the number of thrombi of diameter larger than 30 μm embolizing away from the viewing field before vessel occlusion. (4) Occlusion time of the vessel, that is, time required for blood to stop flowing for 10 sec and (5) site of vessel occlusion, that is, at the site of injury or downstream.
- Recombinant
human ADAMTS 13 infusion - Recombinant human ADAMTS13 has been obtained by the methods as described in Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz H P, and Scheiflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100(10):3626-3632. Recombinant
human ADAMTS 13 protein was dissolved in 150 mmol NaCl/20 mmol Histidin/2% Sucrose/0.05% Crillet 4HP (Tween 80), pH 7.4 (Baxter Bioscience, Vienna, Austria). Recombinanthuman ADAMTS 13 was injected i.v. (3460 U/kg mouse). Levels of human ADAMTS13 antigen were determined by a slight modification of the ELISA method described by Rieger (Rieger M, Kremer Hovinga J A, Konetschny C, Herzog A, Koller L, Weber A, Remuzzi G, Dockal M, Plaimauer B and Scheiflinger F. Relation between ADAMTS13 Activity and ADAMTS13 Antigen Levels in Healthy Donors and Patients with Thrombotic Microangiopathies (TMA). Thrombosis and Hemostasis 2006;95(2):212-20) and r-hu ADAMTS13 activity was determined according to Gerritsen (Gerritsen H E, Turecek P L, Schwarz H P, Laemmle B, and Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999;82:1386-1389). 1 U corresponds to the level of ADAMTS13 activity in pooled normal human plasma. -
Recombinant mouse ADAMTS 13 infusion - Recombinant mouse ADAMTS13 has been obtained by the methods as described in Bruno K, Volkel D, Plaimauer B, Antoine G, Pable S, Motto D G, Lemmerhirt H L, Dorner F, Zimmermann K, and Scheiflinger F. Cloning, expression and functional characterization of the full-length murine ADAMTS-13. J Thromb Haemost 2005;3(5):1064-1073.
Recombinant mouse ADAMTS 13 protein was dissolved in 150 mmol NaCl/20 mmol Histidin/2% Sucrose/0.05% Crillet 4HP (Tween 80), pH 7.4 (Baxter Bioscience, Vienna, Austria). - Flow chamber studies
- Flow chamber studies were performed as described in Bergmeier (Bergmeier W, Burger P C, Piffath C L, Hoffmeister K M, Hartwig J H, Nieswandt B, and Wagner D D. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003;102:4229-4235). Briefly, platelets were isolated from heparinized whole blood, washed in modified Tyrode-HEPES buffer, and labeled with 2.5 μg/mL calcein. Platelet poor whole blood was reconstituted with labeled platelets before perfusion in a parallel-plate flow chamber system coated with 100 m/mL collagen Horm (NYCOMED, Munich, Germany) for 1 h at RT. Where indicated, samples were pretreated with 30 μg/ml JON/A (emfret Analytics, Wuerzburg, Germany) for 10 min prior to perfusion. Platelet adhesion was visualized with an Axiovert 135 inverted microscope (Zeiss). The percentage of surface area covered by fluorescent platelets was analyzed using NIH Image 1.61 software by an individual blinded to genotypes.
- Statistical analysis
- Results are reported as the mean±SEM. The statistical significance of the difference between means was assessed by the Student's t test.
- Discussion of the experimental results
- The experimental results have defined a key role for ADAMTS13 in preventing thrombi formation in activated microvenules and excessive thrombus formation in the injured arterioles of mice. Using intravital microscopy, it is shown in vivo in
ADAMTS 13−/−mice that activating venules (25-30 μm) results in platelet aggregation leading to microthrombi formation (FIG. 1 ). Microthrombi do not form in the venules of WT mice treated identically. When released from the activated endothelium, these microthrombi can travel downstream and cause occlusion elsewhere in the small capillaries where they cannot pass, thus leading to organ ischemia. Patients suffering from TTP often have microthrombi that are formed in the microvasculature of organs: like brain, heart, pancreas, spleen, kidney and mesentery. Various agents including viruses, bacterial shiga toxins, drugs such as ticlopidine and clopidogrel, antibodies and immune complexes can trigger vascular activation perhaps inducing Weibel-Palade body release. In arterioles (which have higher shear stress) treated identically with A23187 no thrombi could be seen. This is because either Weibel-Palade bodies were not released in these vessels or, more likely, vWF is washed too quickly from the endothelial surface to promote platelet adhesion. - Autoantibodies neutralizing human ADAMTS13 are a major cause of the acquired type of TTP. Infusion of anti-ADAMTS13 antibody in the WT mice resulted in prolonged adhesion of platelets to secreted vWF and platelet string formation on the stimulated endothelium (
FIG. 2A ) that was similar to that seen in the Adamts13−/−mice. The strings of platelets, varying from approx. 20-70 μm in length, can be seen anchored to the endothelium (FIG. 2B ). Platelet strings and aggregates were frequently seen in the Adamts13−/−mice when challenged with Weibel-Palade body secretagogues such as histamine, inflammatory cytokine TNF-α and activated platelets. Infusion of the r-hu ADAMTS13 protein in the Adamts13−/−mice challenged with histamine inhibits the platelet strings formation. These strings are cleaved at the upstream end. - Activation of microvenules (25 to 30 μm) with A23187 results in platelet aggregates leading to thrombi formation in the Adamts13 WT mice infused with anti-ADAMTS13-Ab (
FIG. 3 ). However, these thrombi embolized rapidly, similar to those in the Adamts13−/31 mice. Microthrombi formation can be also induced in the WT mice on a C57BL/6 background infused with inhibitory antibody. Thus the mouse infused with anti-ADAMTS 13 Ab is in many aspects a good model for acquired TTP. In addition, it demonstrates the role of the ADAMTS13 in preventing platelet aggregation in the circulation. - vWF through its receptors, GPIbα and αIIbβ3, contributes to platelet function in initiating platelet aggregation and progression of thrombus formation. The experimental observations that platelet-endothelial interactions are prolonged and that the endothelial activation results in microthrombi in the Adamts13−/31 mice led to the hypothesis that ADAMTS13 deficiency might accelerate thrombus formation in injured arterioles. Indeed, the absence of ADAMTS13 promoted all aspects of thrombus growth. Unexpectedly, even more platelets deposited on the denuded vessel wall after 2-3 mins of injury in the Adamts13−/31 mice as compared with WT (
FIG. 5A ). Since early platelet deposition in arterioles is vWF dependent, it means that either plasma ADAMTS13 reduces vWF incorporation into the basement membrane when it is exposed to blood, or that it digests vWF already present in the extra-cellular matrix. The rapid thrombus growth and occlusion in Adamts13−/31 mice indicates that ADAMTS13 might cleave vWF multimers incorporated in the thrombus. - It has been suggested that cleavage of VWF domain A2 by ADAMTS13 is facilitated by the binding of VWF to GPIba. Thus, the VWF-GPIb interaction within the thrombus may negatively regulate thrombus growth. Thrombus formation under venous and arterial flow conditions also depends on major integrin αIIbβ3. The present examples at arteriolar shear rates show that ADAMTS13 modulates the growing thrombus only when platelets in the thrombus express an active beta3 integrin. Under these in vitro and in vivo experimental conditions, ADAMTS13-deficiency did not promote thrombus growth if the major platelet integrin was absent or inhibited (
FIG. 6 ). - In order to inhibit the fast thrombus growth seen in the ADAMTS13−/−mice, r-hu ADAMTS13 was infused into Adamts13−/31 and WT mice prior to injury. The anti-thrombotic effect of the r-hu ADAMTS13, although highly statistically significant, varied among the animals (
FIGS. 7A and 7B ). Some mice did not respond to r-hu ADAMTS13 treatment. It is possible that in these mice r-hu ADAMTS13 was proteolytically inactivated by thrombin and plasmin produced at the sites of vascular injury. IL-6 and high amounts of vWF released after inflammation or injury could also reduce ADAMTS13 activity. In the vessels which did not occlude, the phenomenon of thrombi disintegrating and reforming is observed (FIG. 7C ). These findings show that ADAMTS13 have both anti-thrombotic and thrombolytic activity. A possible mechanism is ADAMTS13 cleaving the UL-vWF multimers into smaller fragments that are less adhesive or directly cleaving the vWF molecules bridging platelets in a thrombus as is the case in cleavage of platelets attached to strings. In vivo, ADAMTS13 is active at both low venous and high arterial shear stress conditions. It cleaves platelet strings and regulates platelet interaction with the “activated” vessel wall in the venules, prevents thrombi in activated microvenules and modulates the thrombotic response in injured arterioles. - Congenital TTP patients are currently treated by plasma exchange, whereas acquired TTP patients are subjected to plasmapheresis where autoantibodies are removed from the plasma. The antithrombotic and thrombolytic effect of ADAMTS13 protein indicates that besides TTP, e.g. recombinant ADAMTS13 can be used to treat patients suffering with thrombotic disorders due to hereditary defects, inflammatory disease, septic conditions, or venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism. The thrombolytic activity of the ADAMTS13 shows that this protein can be used in combination with other therapies to disintegrate thrombi in clogged arteries or after minor stroke.
- In summary, the experimental data show that the metalloprotease ADAMTS13 negatively regulates thrombosis, which indicates that the molecule has anti-thrombic activity. Thus, e.g., recombinant human ADAMTS13 protein having thrombolytic activity can be used as a therapeutic agent to treat thrombotic disorders.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications and changes in light thereof will be suggested to persons skilled in the art and are to be included within the purview of this application and are considered to be within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/478,520 US20220002703A1 (en) | 2005-06-17 | 2021-09-17 | Adamts13-containing compositions having thrombolytic activity |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69192705P | 2005-06-17 | 2005-06-17 | |
US72932305P | 2005-10-21 | 2005-10-21 | |
US77126506P | 2006-02-07 | 2006-02-07 | |
US11/454,615 US20070015703A1 (en) | 2005-06-17 | 2006-06-16 | ADAMTS13-containing compositions having thrombolytic activity |
US13/747,307 US10233436B2 (en) | 2005-06-17 | 2013-01-22 | ADAMTS13-containing compositions having thrombolytic activity |
US16/262,180 US11124787B2 (en) | 2005-06-17 | 2019-01-30 | ADAMTS13-containing compositions having thrombolytic activity |
US17/478,520 US20220002703A1 (en) | 2005-06-17 | 2021-09-17 | Adamts13-containing compositions having thrombolytic activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/262,180 Division US11124787B2 (en) | 2005-06-17 | 2019-01-30 | ADAMTS13-containing compositions having thrombolytic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220002703A1 true US20220002703A1 (en) | 2022-01-06 |
Family
ID=36956096
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/454,615 Abandoned US20070015703A1 (en) | 2005-06-17 | 2006-06-16 | ADAMTS13-containing compositions having thrombolytic activity |
US13/747,307 Active 2029-02-27 US10233436B2 (en) | 2005-06-17 | 2013-01-22 | ADAMTS13-containing compositions having thrombolytic activity |
US16/262,180 Active 2026-09-10 US11124787B2 (en) | 2005-06-17 | 2019-01-30 | ADAMTS13-containing compositions having thrombolytic activity |
US17/478,520 Abandoned US20220002703A1 (en) | 2005-06-17 | 2021-09-17 | Adamts13-containing compositions having thrombolytic activity |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/454,615 Abandoned US20070015703A1 (en) | 2005-06-17 | 2006-06-16 | ADAMTS13-containing compositions having thrombolytic activity |
US13/747,307 Active 2029-02-27 US10233436B2 (en) | 2005-06-17 | 2013-01-22 | ADAMTS13-containing compositions having thrombolytic activity |
US16/262,180 Active 2026-09-10 US11124787B2 (en) | 2005-06-17 | 2019-01-30 | ADAMTS13-containing compositions having thrombolytic activity |
Country Status (10)
Country | Link |
---|---|
US (4) | US20070015703A1 (en) |
EP (1) | EP1902141B1 (en) |
AT (1) | ATE544866T1 (en) |
AU (1) | AU2006257073B2 (en) |
CA (1) | CA2606351C (en) |
DK (1) | DK1902141T3 (en) |
ES (1) | ES2382104T3 (en) |
HK (1) | HK1118579A1 (en) |
PL (1) | PL1902141T3 (en) |
WO (1) | WO2006133955A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PL1902141T3 (en) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Adamts13-comprising compositions having thrombolytic activity |
FR2918375B1 (en) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | USE OF A CHROMATOGRAPHY MEDIUM TO REDUCE THE QUANTITY OF ADAMTS13 IN A PLASMA-DERIVED SOLUTION |
EP2288377A1 (en) * | 2008-05-12 | 2011-03-02 | Immune Disease Institute | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
US9587249B2 (en) * | 2008-10-27 | 2017-03-07 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
JP6111016B2 (en) | 2008-12-05 | 2017-04-05 | バクスアルタ ゲーエムベーハー | Method for measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and use thereof |
JP5411582B2 (en) * | 2009-06-02 | 2014-02-12 | 一般財団法人化学及血清療法研究所 | Cell transplantation enhancement adjuvant by ADAMTS13 |
US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
KR20220139456A (en) | 2009-09-21 | 2022-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Stabilized liquid and lyophilized adamts13 formulations |
BR112012008970A2 (en) * | 2009-10-16 | 2019-12-10 | Omeros Corp | use of a composition and composition |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
MX355648B (en) | 2011-04-08 | 2018-04-26 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation. |
AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
US9976143B2 (en) | 2014-10-03 | 2018-05-22 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
CN105991563B (en) * | 2015-02-05 | 2020-07-03 | 阿里巴巴集团控股有限公司 | Method and device for protecting security of sensitive data and three-party service system |
WO2016186994A1 (en) * | 2015-05-15 | 2016-11-24 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of thrombotic microangiopathy |
EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
EP3401685B1 (en) | 2016-01-08 | 2021-12-01 | Kyoto University | Diagnostic method and medicine comprising adamts13 as main ingredient |
CA3031740A1 (en) * | 2016-08-04 | 2018-02-08 | Baxalta Incorporated | Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
CN111278991B (en) | 2017-08-25 | 2022-04-01 | 斯托克制药公司 | Antisense oligomers for the treatment of conditions and diseases |
US20220339266A1 (en) * | 2019-10-04 | 2022-10-27 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
EP4127158A2 (en) | 2020-04-02 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
CA3173647A1 (en) | 2020-05-11 | 2021-11-18 | Isabel AZNAREZ | Opa1 antisense oligomers for treatment of conditions and diseases |
WO2021234458A1 (en) | 2020-05-22 | 2021-11-25 | Takeda Pharmaceutical Company Limited | Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease |
CA3201986A1 (en) * | 2020-11-18 | 2022-05-27 | Green Cross Corporation | Adamts13 variant having increased escaping rate or activity against autoantibody |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082218A (en) * | 1973-11-10 | 1975-07-03 | ||
US4791138A (en) * | 1983-12-14 | 1988-12-13 | The Upjohn Company | Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors |
EP1200124B1 (en) * | 1999-07-13 | 2008-09-10 | Bolder Biotechnology, Inc. | Erythropoietin-immunoglobulin fusion proteins |
US6926894B2 (en) * | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
JP2003284570A (en) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | VON WILLEBRAND FACTOR (vWF) BREAKING ENZYME |
US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
US20030073115A1 (en) * | 2002-09-16 | 2003-04-17 | Shyam Ramakrishnan | Regulation of human galanin receptor-like g protein coupled receptor |
US7763430B2 (en) * | 2003-04-22 | 2010-07-27 | Baxter International Inc. | Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies |
EP1568782A1 (en) * | 2004-02-25 | 2005-08-31 | Clemens Bockmeyer | Diagnosis and therapy of ADAMTS-13 associated diseases |
PL1902141T3 (en) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Adamts13-comprising compositions having thrombolytic activity |
-
2006
- 2006-06-16 PL PL06754405T patent/PL1902141T3/en unknown
- 2006-06-16 US US11/454,615 patent/US20070015703A1/en not_active Abandoned
- 2006-06-16 DK DK06754405.6T patent/DK1902141T3/en active
- 2006-06-16 WO PCT/EP2006/005800 patent/WO2006133955A1/en not_active Application Discontinuation
- 2006-06-16 ES ES06754405T patent/ES2382104T3/en active Active
- 2006-06-16 EP EP06754405A patent/EP1902141B1/en active Active
- 2006-06-16 CA CA2606351A patent/CA2606351C/en not_active Expired - Fee Related
- 2006-06-16 AU AU2006257073A patent/AU2006257073B2/en active Active
- 2006-06-16 AT AT06754405T patent/ATE544866T1/en active
-
2008
- 2008-09-05 HK HK08109912.8A patent/HK1118579A1/en unknown
-
2013
- 2013-01-22 US US13/747,307 patent/US10233436B2/en active Active
-
2019
- 2019-01-30 US US16/262,180 patent/US11124787B2/en active Active
-
2021
- 2021-09-17 US US17/478,520 patent/US20220002703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10233436B2 (en) | 2019-03-19 |
HK1118579A1 (en) | 2009-02-13 |
AU2006257073B2 (en) | 2011-08-04 |
DK1902141T3 (en) | 2012-05-07 |
US11124787B2 (en) | 2021-09-21 |
US20070015703A1 (en) | 2007-01-18 |
ATE544866T1 (en) | 2012-02-15 |
EP1902141B1 (en) | 2012-02-08 |
AU2006257073A1 (en) | 2006-12-21 |
US20130136732A1 (en) | 2013-05-30 |
EP1902141A1 (en) | 2008-03-26 |
PL1902141T3 (en) | 2012-12-31 |
WO2006133955A8 (en) | 2007-11-29 |
CA2606351C (en) | 2016-12-13 |
CA2606351A1 (en) | 2006-12-21 |
WO2006133955A1 (en) | 2006-12-21 |
US20190161746A1 (en) | 2019-05-30 |
ES2382104T3 (en) | 2012-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220002703A1 (en) | Adamts13-containing compositions having thrombolytic activity | |
Chauhan et al. | Systemic antithrombotic effects of ADAMTS13 | |
JP6258390B2 (en) | Methods and compositions for treating cerebral bleeding conditions | |
JP6998333B2 (en) | Subcutaneous administration of ADAMTS13 | |
US20150258168A1 (en) | Modulation of podoplanin mediated platelet activation | |
JP2009539757A (en) | ADAMTS13-containing composition having thrombolytic activity | |
Chauhan et al. | of ADAMTS13 | |
WO2023152291A1 (en) | Methods and pharmaceutical composition for treating thrombotic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WAGNER, DENISA;CHAUHAN, ANIL KUMAR;REEL/FRAME:057951/0057 Effective date: 20060908 Owner name: THE CHILDREN'S HOSPITAL CORPORATION, MASSACHUSETTS Free format text: MERGER;ASSIGNOR:IMMUNE DISEASE INSTITUTE, INC.;REEL/FRAME:057953/0397 Effective date: 20120928 Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHEIFLINGER, FRIEDRICH;PLAIMAUER, BARBARA;SIGNING DATES FROM 20060908 TO 20060912;REEL/FRAME:057951/0570 Owner name: BAXTER INTERNATIONAL INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHEIFLINGER, FRIEDRICH;PLAIMAUER, BARBARA;SIGNING DATES FROM 20060908 TO 20060912;REEL/FRAME:057951/0570 Owner name: BAXALTA GMBH, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXTER INTERNATIONAL INC.;BAXTER HEALTHCARE SA;REEL/FRAME:057969/0590 Effective date: 20150811 Owner name: BAXALTA INCORPORATED, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXTER INTERNATIONAL INC.;BAXTER HEALTHCARE SA;REEL/FRAME:057969/0590 Effective date: 20150811 Owner name: IMMUNE DISEASE INSTITUTE, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:057968/0860 Effective date: 20070605 |
|
AS | Assignment |
Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND Free format text: CHANGE OF ADDRESS;ASSIGNOR:BAXALTA HEALTHCARE S.A.;REEL/FRAME:057978/0714 Effective date: 20170502 Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXALTA GMBH;BAXALTA INCORPORATED;REEL/FRAME:057972/0407 Effective date: 20201205 Owner name: CHILDREN'S MEDICAL CENTER CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE CHILDREN'S HOSPITAL CORPORATION;REEL/FRAME:057972/0378 Effective date: 20170721 Owner name: BAXALTA GMBH, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXTER INTERNATIONAL INC.;BAXTER HEALTHCARE SA;REEL/FRAME:057978/0001 Effective date: 20150811 Owner name: BAXALTA INCORPORATED, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXTER INTERNATIONAL INC.;BAXTER HEALTHCARE SA;REEL/FRAME:057978/0001 Effective date: 20150811 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |